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1 Introduction
Many countries have national guidelines for performing
economic evaluations in healthcare.1 These guidelines
should ensure the comparability and quality of such eval-
uations, which should facilitate making well informed
policy decisions regarding reimbursement of interventions.
Given the developments in both the methodology and
policy context of economic evaluation of healthcare
interventions, these guidelines require periodical revision.
Recently, the Dutch National Health Care Institute issued
new guidance for economic evaluations in healthcare [1].
The new guidelines update and replace three separately
published previous guidelines: those for pharmacoeco-
nomic evaluation (latest version 2006), outcomes research
(latest version 2008) as well as the Dutch costing manual
(latest version 2010). In this editorial, we highlight the
distinguishing features of the new Dutch guidelines.
Moreover, we highlight which developments, in our opin-
ion, are desirable in coming updates, but are still in
development or controversial.
2 Unchanged Features
2.1 Societal Perspective
A key feature of guidelines is which perspective they
prescribe researchers to take in an evaluation. In line with
the welfare economic roots of economic evaluation, influ-
ential textbooks as well as all previous Dutch guidelines,
the new guidelines prescribe taking a societal perspective.
This implies that all significant societal costs and benefits
need to be included in the analysis, regardless of where
these fall. Thus, evaluations should also include costs and
benefits that fall outside the healthcare sector, such as time
costs for patients (e.g. time lost from paid work, unpaid
work or leisure time), travel costs, costs related to informal
care (e.g. time of caregivers), costs of special education or
those related to criminal activity.
2.2 Productivity Costs
Productivity costs are an important example of costs falling
outside the healthcare sector. When productive people,
either paid or unpaid, become less productive (due to ill-
ness, disability, death or treatment), this causes real soci-
etal costs. The guidelines indicate how to value these
components, including the often ignored unpaid work
[2, 3]. For absenteeism from paid work, the friction cost
method is prescribed as the most accurate estimation of
societal costs [4, 5]. This method limits productivity to the
period it takes to replace an absent worker [6]. The mea-
surement and valuation of production losses due to
& Werner Brouwer
brouwer@bmg.eur.nl
1 Institute for Medical Technology Assessment, Erasmus
University Rotterdam, PO Box 1738, 3000 DR Rotterdam,
The Netherlands
2 Dutch National Health Care Institute, Diemen, The
Netherlands
3 Institute of Health Policy and Management, Erasmus
University Rotterdam, Rotterdam, The Netherlands
1 For an overview of guidelines around the world visit http://www.
ispor.org/PEguidelines/index.asp.
PharmacoEconomics (2016) 34:1071–1074
DOI 10.1007/s40273-016-0431-y
presenteeism are acknowledged as relevant. The costing
manual (as part of the guidelines) indicates that produc-
tivity losses, including presenteeism, can be measured
using, for example, the iMTA Productivity Cost Ques-
tionnaire (iPCQ) instrument [7].2 Unpaid work is valued at
€14 per hour.
2.3 Informal Care
Another important cost (and effect) category is informal
care, which commonly is a large part of total care provided
to patients. Several methods for measuring, valuing and
including these costs exist [8], but the current guidelines
suggest they should be included on the cost side of the
economic evaluation. This facilitates their inclusion in the
most common type of economic evaluation: cost–utility
analysis.
2.4 Cost–Utility Analysis
Cost–utility analysis, using quality-adjusted life-years
(QALYs) as outcome, continues to be the reference case in the
current guidelines. Effects in terms of health-related quality
of life have to be captured with EQ-5D-5L valued with Dutch
population preferences [9]. Remarkably, EQ-5D-5L scores
have to be presented in the reference case, even when they
might be considered inappropriate. Then, alternative mea-
sures can be presented alongside EQ-5D-5L outcomes.
2.5 Differential Discounting
Discounting costs and effects in economic evaluations is
much debated (e.g. [10]). The previous guidelines (from
2006) already prescribed differential discounting (4 % for
costs and 1.5 % for effects) rather than an equal discount rate
of 4 %, to account for the growing value of health benefits in
the future [11]. The current guideline also prescribes differ-
ential discounting; using the same rates (4 and 1.5 %).
3 New Features
The new guidelines also include new elements, reflecting
the methodological developments in performing economic
evaluations in healthcare. We highlight three of them.
3.1 Value of Information Analysis
Previous guidelines requested information on the uncer-
tainty of the outcome of economic evaluations through
univariate sensitivity analyses, probabilistic sensitivity
analyses (PSA) and scenario analyses. The new guidelines
require quantifying uncertainty through value of informa-
tion analysis for all uncertain policy decisions, which can
help in decision making, using conditional reimbursement
schemes and priority setting of further research [12, 13]. In
all instances where there is decision uncertainty, i.e. PSA
indicates that the probability of an intervention being cost
effective (given a relevant cost-effectiveness threshold) is
\100 %, a value of information analysis is required.
3.2 Inclusion of Indirect Medical Costs
in Life-Years Gained
Another major and quite unique change is the requirement
to include so-called unrelated indirect medical costs in life-
years gained. For example, when assessing the cost effec-
tiveness of heart surgery, the costs related to treating hip
fractures in gained life-years after successful heart surgery
are also to be included. These costs were explicitly
excluded from consideration in the previous guidelines,
and this is still the case in most other guidelines, including
those of NICE [14]. The inclusion of these latter costs has
been much debated [15], but the case for their inclusion is
strong [16]. Especially given that the health gains due to
these unrelated costs typically are (implicitly) included in
economic evaluations, making their exclusion inconsistent
from both a societal and a healthcare perspective [17].
These unrelated healthcare costs can be estimated, cor-
recting for the characteristics of the patients involved,
using a simple tool that was recently developed [18].3
Clearly, including these costs can increase incremental
cost-effectiveness ratios (i.e. decrease cost effectiveness of
life-prolonging interventions), which may result in differ-
ent reimbursement decisions that collectively increase
health gained per euro, but which may also raise important
ethical and policy questions. Given the new Dutch guide-
lines, these questions cannot and should not be circum-
vented by ignoring these real costs.
3.3 Beyond Medicines and Curative Care
A final important development is the explicit attention in
the guidelines for methodological issues that arise in sec-
tors other than the conventional areas of curative care and
pharmaceuticals. While for these other sectors the now-
included reference case requires QALY measurement with
EQ-5D-5L-based quality-of-life corrections, it is
acknowledged that this outcome measure may have limi-
tations in particular contexts. Issues may specifically arise
in economic evaluations in the contexts of prevention (e.g.
2 Questionnaires for measuring and valuing productivity costs and
informal care can be found here: http://www.imta.nl/questionnaires. 3 The tool can also be found here: http://www.imta.nl/paid.
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uncertainty and modelling based on intermediate out-
comes), diagnostics (e.g. consequences of false positives
and negatives as well as value assessment in patients),
medical devices (e.g. value of user friendliness), long-term
care (e.g. wellbeing rather than health improvement as the
goal) and forensic (e.g. reduction of criminal activity as the
goal of an intervention). Many of these issues pertain to
accurately capturing the value of interventions when this
exceeds or deviates from health gains (in terms of length of
life and quality of life as measured with the EQ-5D). The
guidelines suggest other possibilities, ranging from mea-
suring patients’ preferences for medical devices, use of
effectiveness measures such as ‘criminal-activity-free
years’ in forensic interventions, to the use of new instru-
ments such as the ICECAP (Icepop Capability) measure
[19] in case of long-term and social care [20]. For the
purpose of standardization, the ICECAP is recommended
in the guideline for outcome assessment in this field, be it
alongside EQ-5D. This marks the broadening of the scope
of the guidelines and use of economic evaluations in
healthcare. The guideline also highlights the need for
Multi-Criteria Decision Analysis in this context.
4 What is Expected and Desired in Future
Updates?
The new Dutch guidelines present a long awaited update
incorporating important improvements in theory and
methodology of economic evaluations. A committee with
broad representation of health technology assessment
(HTA) experts was involved in creating these new guide-
lines. Cyclic updates are foreseen to guarantee that the
guidelines keep up with methodological advances and are
useful in the policy context. Below, we suggest four topics
that could be included in future versions of the Dutch
guidelines.
4.1 Expanding the Scope of Economic Evaluations
The current guidelines began the first step in broadening
the scope of economic evaluations by looking at the
specific issues related to, for instance, long-term care. It is
important and expected that future guidelines will develop
stronger and clearer guidance as to how to perform eco-
nomic evaluations in these contexts. This will probably
include a further standardization of non-QALY outcomes,
such as wellbeing measures like the ICECAP [19]. It may
also involve guidance on how to obtain preferences from
patients through methods such as discrete choice experi-
ments. Wellbeing measures may well become the preferred
outcome measures in economic evaluations in non-curative
settings, rather than being presented next to QALY
estimates. However, it has to be acknowledged that expe-
rience with these instruments is currently limited. More-
over, there may be other pressing challenges related to
obtaining good quality economic evaluations in the non-
curative setting, most notably those related to adequate
study designs for assessing comparative effectiveness of
interventions. Indeed, appropriate wellbeing measures
should be used in the context of well designed studies
capable of detecting the wellbeing changes due to
interventions.
4.2 Inclusion of Non-Medical Consumption
Given that Dutch guidelines prescribe taking a societal
perspective and that, where relevant, productivity costs and
indirect medical costs in gained life-years are now inclu-
ded, it is likely that the inclusion of non-medical con-
sumption in life-years gained (housing, food, etc.) will gain
more attention. Similar to indirect medical costs, prolonged
survival of individuals increases such non-medical con-
sumption. Moving towards a more complete and consistent
trade-off of costs and effects will require inclusion of these
costs in evaluations, as well as more discussion on whether
the QALY adequately captures the related benefits [21, 22].
We do foresee, however, that inclusion of these costs will
require both methodological work as well as further dis-
cussion to increase the acceptance of their inclusion.
4.3 Inclusion of QALY Variation
The current guideline prescribes the use of EQ-5D with
Dutch tariffs obtained in the general public in all evalua-
tions. This guidance enhances the uniform assessment of
QALY gains, but also ignores important heterogeneity in
QALY instruments. One important missed issue is the
valuation of health states by patients themselves. Using
both patient and general population values can inform the
decision makers about the likelihood of adaptation to a
condition, and use this information in the decision-making
context. In a context of limited resources, decision makers
might, for instance, use this information to, ceteris paribus,
prioritize treatments of conditions for which adaptation is
less likely and, therefore, treatment effects from a patient
perspective are relatively large [23].
4.4 Two Perspectives and Costs of Displacement
Economic evaluations ultimately aim to inform resource
allocation decisions in healthcare. The current framework
for decision making in The Netherlands adopts a societal
perspective, informally using an (equity weighted) thresh-
old value for QALY gains that represents the social will-
ingness to pay for QALY gains—the trade-off between
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health and other consumption. However, a full assessment,
in the context of limited healthcare budgets, also requires
knowledge about the opportunity costs within the health-
care sector [11, 17]. An intermediate step is to present the
results from two perspectives: the societal and the health-
care perspective [24]. This allows relevant stakeholders to
understand the tension between the two perspectives (if
any).
Meaningfully interpreting the results from both per-
spectives still requires appropriate threshold values from
both perspectives. While some experience with using
equity-weighted, societal values of QALYs is present in the
Dutch context, more knowledge on the opportunity costs of
spending within the Dutch healthcare sector is required. In
the coming period, more research can be devoted to this
issue, along with gaining experience in the decision-mak-
ing process using two perspectives.
5 Conclusion
The new Dutch guidelines are an important step forward in
improving the requirements for economic evaluations in
healthcare in the context of reimbursement decisions. We
feel that the changes have moved the guidelines from good
to better. We also feel that the foreseen periodical updates
of the guidelines will allow further improvement in the
future.
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